First line chemotherapy for SCLC: The West of Scotland SCLC retrospective database

被引：0
|
作者：
Slater, S. [1 ]
McKay, S. [1 ]
MacLaren, V. [1 ]
Hicks, J. [1 ]
机构：
[1] West Scotland Canc Ctr, Glasgow, Lanark, Scotland
来源：
LUNG CANCER | 2014年 / 83卷
关键词：
D O I：
10.1016/S0169-5002(14)70179-5
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
178
引用
收藏
页码：S65 / S66
页数：2
相关论文
共 50 条
  • [41] Evolution of chemotherapy for small cell lung cancer (SCLC).
    Vaslamatzis, M
    Alexopoulos, C
    Patila, E
    Filadetaki, V
    Rontoyanni, D
    ANNALS OF ONCOLOGY, 2000, 11 : 121 - 121
  • [42] Zweitlinientherapie des kleinzelligen Lungenkarzinoms (SCLC)Second-line therapy for small cell lung cancer (SCLC)
    F. Griesinger
    T. Overbeck
    N. Niederle
    Der Onkologe, 2005, 11 (7): : 730 - 740
  • [43] Plasma Vitamin D Level is an Independent Prognosis Factor in SCLC Patients Treated with Platinum Plus Etoposide as First-Line Chemotherapy
    Wang, X.
    Zhang, C.
    Ma, K.
    Li, W.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S795 - S795
  • [44] Surufatinib plus toripalimab in patients with advanced small cell lung cancer (SCLC) after failure of first-line systemic chemotherapy
    Cheng, Y.
    Shen, L.
    Yu, X.
    Chen, Z.
    Song, L.
    Zhang, Y.
    Wu, C.
    Lu, M.
    Gao, H.
    Chen, W.
    Yang, M.
    Ma, Y.
    Zhou, J.
    Shi, H.
    Tan, P.
    Fan, S.
    Su, W.
    ANNALS OF ONCOLOGY, 2021, 32 : S1448 - S1449
  • [45] MOZART: Phase II Trial of Monalizumab, Durvalumab, and Platinum-based Chemotherapy for First-Line Treatment of Extensive Stage SCLC
    Mamdani, H.
    Kim, S.
    Gentzler, R.
    Furqan, M.
    Shields, M. D.
    Jalal, S. I.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S207 - S207
  • [46] Irinotecan or etoposide as front-line therapy for SCLC?
    Johnson, Faye M.
    Glisson, Bonnie S.
    NATURE REVIEWS CLINICAL ONCOLOGY, 2009, 6 (10) : 562 - 563
  • [47] Outcomes of small cell lung cancer (SCLC) patients treated with second-line chemotherapy (SL) with CPT-11: A retrospective analysis
    Lopez Jimenez, A.
    Esquerdo, G.
    Barrajon, E.
    Del Rio Pazos, L.
    Cervera, J.
    Diaz, N.
    Angeles Oyonarte, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [48] Irinotecan or etoposide as front-line therapy for SCLC?
    Faye M. Johnson
    Bonnie S. Glisson
    Nature Reviews Clinical Oncology, 2009, 6 : 562 - 563
  • [49] CASPIAN: Phase 3 Study of First-Line Durvalumab ± Tremelimumab plus Platinum-Based Chemotherapy vs Chemotherapy Alone in ED-SCLC
    Paz-Ares, L.
    Jiang, H.
    Huang, Y.
    Dennis, P.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2398 - S2398
  • [50] Maintenance with Lanreotide in SCLC Patients, Expressing Somatostatine Receptors, after Response to First Line Therapy
    Santo, Antonio
    Roca, Elisa
    La Russa, Francesca
    Grossi, Francesco
    Genova, Carlo
    Favaretto, Adolfo G.
    Sibau, Angela
    Follador, Alessandro
    Bearz, Alessandra
    Romano, Giampiero
    Papi, Maximilian
    Caprioli, Alberto
    Catino, Annamaria
    Galetta, Domenico
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S626 - S626
12345